• Publishes critical reviews of broad interest on the treatment of neurologic disorders by renowned experts.
  • Covers emerging treatments for neurologic disorders.
  • Publishes cutting edge original translational research in unmet medical needs for diseases of the nervous system.
  • Explores the molecular underpinnings of neurologic diseases as rationale for targeted therapies.
  • Provides a platform for publishing points-of-view by key opinion leaders on current hot topics.

Journal information

  • M. Maral Mouradian
Publishing model
Hybrid (Transformative Journal). Learn about publishing Open Access with us

Journal metrics

7.620 (2020)
Impact factor
8.400 (2020)
Five year impact factor
21 days
Submission to first decision
111 days
Submission to acceptance
597,939 (2020)

Latest articles

Journal updates

  • Announcement: COVID-19 impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

  • Future Theme Issues

    January 2021 
    Therapeutic Frontiers in Sleep Neurology

    Guest Editors:  Aleksander Videnovic (Harvard) and Erik St. Louis (Mayo)

    April 2021
    Neuroimaging Advances in Neurologic/Neurodegenerative Diseases

    Guest Editors:  Andrew Saykin and Shannon Risacher (IUPUI)

    July 2021
    Precision Treatments in Epilepsy

    Guest Editors:  Amy Brooks-Kayal and Scott Demarest (Children's Colorado)

    October 2021
    Neurobiology and Therapeutics of Peripheral Neuropathy

    Guest Editors:  Michael Polydefkis and Charlotte Sumner (JHMI)

  • Future Theme Issues 2022

    January 2022
    Clinical and Translational Advances in Alzheimer's Disease

    Steven T. DeKosky, MD (U of Florida)

    April 2022
    Therapeutic Advances in Neurological Diseases

    Marinos C. Dalakas, MD (Thomas Jefferson University) 
    Heinz Wiendl, MD (University of Münster)

    July 2022
    Motor Neuron Disease, ALS and Neuromuscular Diseases

    Jeffrey D. Rothstein MD, PhD (JHMI)
    Nicholas Maragakis, MD (JHMI)

    October 2022
    Therapeutic Advances in Neuro-oncology

    Patrick Y. Wen, MD (Dana Farber Cancer Institute)
    J. Ricardo McFaline-Figueroa, MD, PhD (Dana Farber Cancer Institute)
    Eudocia Q. Lee, MD, MPH (Dana Farber Cancer Institute)

View all updates

Societies, partners and affiliations


Note this is only the net price. Taxes will be calculated during checkout.
  • Immediate online access with complete access to all articles starting 1997
  • Downloadable in PDF format
  • Subscription expires 12/31/2021

About this journal

Electronic ISSN
Print ISSN
Abstracted and indexed in
  1. CNKI
  2. Chemical Abstracts Service (CAS)
  3. Current Contents/ Life Sciences
  4. Current Contents/Clinical Medicine
  5. Dimensions
  6. EBSCO Biomedical Reference Collection
  8. EBSCO Discovery Service
  10. Google Scholar
  11. Japanese Science and Technology Agency (JST)
  12. Journal Citation Reports/Science Edition
  13. Medline
  14. Meta
  15. Naver
  16. OCLC WorldCat Discovery Service
  17. ProQuest Biological Science Database
  18. ProQuest Central
  19. ProQuest Health & Medical Collection
  20. ProQuest Health Research Premium Collection
  21. ProQuest Medical Database
  22. ProQuest Natural Science Collection
  23. ProQuest Neurosciences Abstracts
  24. ProQuest Nursing & Allied Health Database
  25. ProQuest Pharma Collection
  26. ProQuest Psychology Database
  27. ProQuest SciTech Premium Collection
  28. ProQuest-ExLibris Primo
  29. ProQuest-ExLibris Summon
  30. PubMedCentral
  31. Reaxys
  32. SCImago
  33. SCOPUS
  34. Science Citation Index Expanded (SciSearch)
  35. TD Net Discovery Service
  36. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© The American Society for Experimental NeuroTherapeutics, Inc.